Pancreatic Cancer Research

Journal articleCancer Chemother Pharmacol2013

Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.

Journal
Cancer Chemother Pharmacol
Published
9 March 2013
Citations
44

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

Purpose Sorafenib and everolimus are both active against neuroendocrine tumors (NET). Because of potential synergy between VEGF pathway and mTOR inhibitors, we performed a phase I study to evaluate the safety and feasibility of combining sorafenib and everolimus in patients with advanced NET. … Excerpt only: this text is the publisher’s. Read it in full at the source.